Related references
Note: Only part of the references are listed.Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis
Pyeong Hwa Kim et al.
EUROPEAN RADIOLOGY (2021)
Current status and recent advances in resection cavity irradiation of brain metastases
Giuseppe Minniti et al.
RADIATION ONCOLOGY (2021)
Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo plus ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
Jarushka Naidoo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Nodular Leptomeningeal Disease-A Distinct Pattern of Recurrence After Postresection Stereotactic Radiosurgery for Brain Metastases: A Multi-institutional Study of Interobserver Reliability
Brandon E. Turner et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Stereotactic Radiosurgery for Resected Brain Metastases: Single-Institutional Experience of Over 500 Cavities
Siyu Shi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
The Promise of Combining Radiation Therapy With Immunotherapy
Justin C. Jagodinsky et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Priscilla K. Brastianos et al.
NATURE MEDICINE (2020)
Multi-institutional Analysis of Prognostic Factors and Outcomes After Hypofractionated Stereotactic Radiotherapy to the Resection Cavity in Patients With Brain Metastases
Kerstin A. Eitz et al.
JAMA ONCOLOGY (2020)
Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data
Eric J. Lehrer et al.
RADIOTHERAPY AND ONCOLOGY (2019)
A multi-institutional analysis of presentation and outcomes for leptomeningeal disease recurrence after surgical resection and radiosurgery for brain metastases
Roshan S. Prabhu et al.
NEURO-ONCOLOGY (2019)
Association of Neurosurgical Resection With Development of Pachymeningeal Seeding in Patients With Brain Metastases
Daniel N. Cagney et al.
JAMA ONCOLOGY (2019)
Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity
Giuseppe Minniti et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Image-Guided, Linac-Based, Surgical Cavity-Hypofractionated Stereotactic Radiotherapy in 5 Daily Fractions for Brain Metastases
Hany Soliman et al.
NEUROSURGERY (2019)
Surgery Followed by Hypofractionated Radiosurgery on the Tumor Bed in Oligometastatic Patients With Large Brain Metastases. Results of a Phase 2 Study
Pierina Navarria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Single versus Multifraction Stereotactic Radiosurgery for Large Brain Metastases: An International Meta-analysis of 24 Trials
Eric J. Lehrer et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
Linda Chen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Postoperative radiosurgery for the treatment of metastatic brain tumor: Evaluation of local failure and leptomeningeal disease
Paul M. Foreman et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2018)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies
Ee Siang Choong et al.
EUROPEAN JOURNAL OF CANCER (2017)
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial
Paul D. Brown et al.
LANCET ONCOLOGY (2017)
Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial
Anita Mahajan et al.
LANCET ONCOLOGY (2017)
Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment
Erik S. Anderson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
E. Le Rhun et al.
ANNALS OF ONCOLOGY (2017)
Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy
K. A. Ahmed et al.
ANNALS OF ONCOLOGY (2016)
Surgical Resection of Brain Metastases and the Risk of Leptomeningeal Recurrence in Patients Treated With Stereotactic Radiosurgery
Matthew D. Johnson et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Single-Fraction Versus Multifraction (3 x 9 Gy) Stereotactic Radiosurgery for Large ( > 2 cm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain Necrosis
Giuseppe Minniti et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
Current clinical trials testing the combination of immunotherapy with radiotherapy
Josephine Kang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery
Francesco Cicone et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
A Phase 2 Trial of Stereotactic Radiosurgery Boost After Surgical Resection for Brain Metastases
Cameron Brennan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Endoscopic endonasal transsphenoidal approach to large and giant pituitary adenomas: institutional experience and predictors of extent of resection
Kyle Juraschka et al.
JOURNAL OF NEUROSURGERY (2014)
Early Gamma Knife stereotactic radiosurgery to the tumor bed of resected brain metastasis for improved local control
Christian Iorio-Morin et al.
JOURNAL OF NEUROSURGERY (2014)
Multidose Stereotactic Radiosurgery (9 Gy x 3) of the Postoperative Resection Cavity for Treatment of Large Brain Metastases
Giuseppe Minniti et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Predicting Tumor Control After Resection Bed Radiosurgery of Brain Metastases
Neal Luther et al.
NEUROSURGERY (2013)
Current Dosing Paradigm for Stereotactic Radiosurgery Alone After Surgical Resection of Brain Metastases Needs to Be Optimized for Improved Local Control
Roshan Prabhu et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
Paul W. Sperduto et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
Martin Kocher et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
M. Zahidunnabi Dewan et al.
CLINICAL CANCER RESEARCH (2009)
Share Paper
